Conclusions: The ARMYDA-ACS trial indicates that even short-term pretreatment with atorvastatin may improve outcomes in patients with ACS undergoing early invasive strategy.

• 结论：ARMYDA-ACS试验提示，对于行介入治疗的急性冠脉综合征患者来说，即使是阿托伐他汀短期预处理也能改善预后。